| 包装: | 1 Set |
| 市场价: | 900元 |
| Formulation: | DMSO solution | ||||||||||
| Long Term Storage: | -20°C | ||||||||||
| Kit/Set Contains: | Contains 25μl (10mM) each of the following inhibitors:
|
ABT-737是Bcl-xL、Bcl-2和Bcl-w的BH3模拟抑制剂，EC50值分别为78.7 nM、30.3 nM和197.8 nM，对Mcl-1、Bcl-B和Bfl-1没有抑制作用。
WEHI-539对BCL-XL具有高亲和性（亚纳摩尔）和选择性，IC50值为1.1 nM，通过选择性拮抗BCL-XL的促存活活性，从而杀死细胞。
TW-37是一种新型非肽类抑制剂，作用于重组Bcl-2、Bcl-xL和Mcl-1，Ki值分别为0.29 μM、1.11 μM和0.26 μM。
ABT-263（Navitoclax）是一种有效的Bcl-xL、Bcl-2和Bcl-w抑制剂，Ki值分别为≤0.5 nM、≤1 nM和≤1 nM。
参考文献：
[1] Tahir S K, Yang X, Anderson M G, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737[J]. Cancer research, 2007, 67(3): 1176-1183.
[2] Lessene G, Czabotar P E, Sleebs B E, et al. Structure-guided design of a selective BCL-XL inhibitor. Nature chemical biology, 2013, 9(6): 390-397.
[3] Wang Z, Azmi A S, Ahmad A, et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer research, 2009, 69(7): 2757-2765.
[4] Mérino D1, Khaw SL, Glaser SP et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.Blood. 2012 Jun 14;119(24):5807-16.
m.cnreagent.com